Evolus (EOLS) Investor Day 2024 summary
Event summary combining transcript, slides, and related documents.
Investor Day 2024 summary
8 Jul, 2026Strategic vision and market positioning
Transitioning from medical aesthetics/pharma to a broader beauty focus, targeting millennials and the $1.5T beauty and wellness market, integrating injectables into mainstream beauty regimens.
Positioned as a performance beauty company, leveraging a cash pay model, design-centric innovation, and digital infrastructure for differentiation.
Achieved 13% U.S. market share in five years, with Jeuveau as the fastest-growing brand and #2 in consumer awareness.
Expanding global reach into seven key markets, aiming for $100 million in international revenue by 2028.
Strong brand identity and consumer-centric approach, with high satisfaction and awareness among millennials and industry recognition.
Product innovation and clinical differentiation
Jeuveau demonstrated superior or comparable efficacy to market leaders in head-to-head Phase III trials, with faster onset and longer duration.
Evolysse, a next-generation HA filler using Cold Technology, showed statistical superiority and efficiency in clinical trials, with less volume needed for better results.
Launch of Form and Smooth fillers in the U.S. within 12 months, covering 95% of HA procedures, with Sculpt and Lips to follow through 2027.
Product launches sequenced with additional indications planned through 2027 and beyond.
High product satisfaction and versatility highlighted by independent clinical investigators and practitioners.
Digital platform and customer engagement
Proprietary digital platform enables seamless ordering, practice management, and patient loyalty programs.
Co-branded media campaigns and hyper-localized marketing drive practice growth and brand awareness, with 1.5 billion impressions delivered.
Evolus Rewards, a text-based loyalty program, is on track for one million enrollments by year-end, supporting high patient retention.
Club Evolus, a new patient membership program, offers affordable, recurring treatments and is set for national launch.
Digital infrastructure supports scalability and integration of new products, enhancing customer and consumer experience.
Latest events from Evolus
- Q3 2025 revenue up 13% to $69M, with strong Jeuveau and Evolysse growth; profitability outlook reaffirmed.EOLS
Q3 20259 Jul 2026 - Record Q2 2024 revenue and first non-GAAP profit drive raised guidance and global expansion.EOLS
Q2 20249 Jul 2026 - Q1 2026 saw 7% revenue growth, positive Adjusted EBITDA, and reaffirmed full-year guidance.EOLS
Q1 20268 Jul 2026 - Evolysse launch and portfolio strategy position the business for accelerated growth and market share gains.EOLS
Barclays 27th Annual Global Healthcare Conference8 Jul 2026 - All proposals were approved with no shareholder questions during the virtual meeting.EOLS
AGM 202611 Jun 2026 - Shelf registration allows up to $250M in securities offerings for the cash-pay aesthetic market.EOLS
Registration filing5 Jun 2026 - Diversified aesthetics portfolio, digital scale, and innovation drive growth and profitability.EOLS
Jefferies Global Healthcare Conference 20264 Jun 2026 - Portfolio expansion, market recovery, and loyalty programs drive strong growth outlook.EOLS
Leerink Global Healthcare Conference 20266 May 2026 - Double-digit growth and digital innovation drive sustained profitability and market expansion.EOLS
Investor presentation4 May 2026